---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-095892"
form_type: "8-K/A"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2026-08-13T20:05:24+00:00"
generated_at: "2026-08-13T20:07:06.274295+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TELA Bio CEO Koblish separation agreement: 12-month salary, equity acceleration

## Summary
- Separation Agreement executed Aug 7, 2026; CEO departure effective Aug 3, 2026.
- Severance: 12 months base salary paid ratably over 12 months; COBRA premiums paid for 12 months.
- All equity awards accelerate and fully vest; option exercise period extended to Dec 31, 2027.
- Performance stock units remain eligible to vest on 2026 revenue/gross margin goals; vest at target on change in control.
- Includes general release and waiver of claims against TELA Bio.

## SEC filing metadata
- accession: 0001104659-26-095892
- form_type: 8-K/A
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2026-08-13T20:05:24+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465926095892/0001104659-26-095892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465926095892/tm2622979d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-095892
- JSON: https://secwatch.observer/filing/0001104659-26-095892.json
- Plain text: https://secwatch.observer/filing/0001104659-26-095892.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.